دورية أكاديمية
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma
| العنوان: | Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma |
|---|---|
| المؤلفون: | Hajek, Roman, Minařík, Jiří, Straub, Jan, Pour, Ludek, Jungova, Alexandra, Berdeja, Jesús G., Boccadoro, Mario, Brozova, Lucie, Spencer, Andrew, Rhee, Frits van, Vela-Ojeda, Jorge, Thompson, Michael A., Abonour, Rafat, Chari, Ajai, Cook, Gordon, Costello, Caitlin L., Davies, Faith E., Hungria, Vania, Lee, Hans C., Leleu, Xavier, Puig, Noemi, Rifkin, Robert M., Terpos, Evangelos, Usmani, Saad Z., Weisel, Katja C., Zonder, Jeffrey A., Bařinová, Magda, Kuhn, Matyáš, Šilar, Jiří, Čápková, Lenka, Galvez, Kenny, Lu, Jin, Elliott, Jennifer, Stull, Dawn Marie, Ren, Kaili, Maisnar, Vladimir |
| المساهمون: | Millennium Pharmaceuticals, Takeda Pharmaceutical Company |
| بيانات النشر: | Future Medicine Future Science |
| سنة النشر: | 2021 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | Effectiveness, Ixazomib, Multiple myeloma, Proteasome inhibitor, Relapsed/refractory, Routine clinical practice |
| الوصف: | [Aim]: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. ; [Results]: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. ; [Conclusion]: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. ; This work was supported by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 1479-6694 1744-8301 |
| العلاقة: | Publisher's version; http://dx.doi.org/10.2217/fon-2020-1225Test; Sí; Future Oncology 17(19): 2499-2512 (2021); http://hdl.handle.net/10261/261619Test; http://dx.doi.org/10.13039/100008373Test |
| DOI: | 10.2217/fon-2020-1225 |
| DOI: | 10.13039/100008373 |
| الإتاحة: | https://doi.org/10.2217/fon-2020-1225Test https://doi.org/10.13039/100008373Test http://hdl.handle.net/10261/261619Test |
| حقوق: | open |
| رقم الانضمام: | edsbas.CD067A47 |
| قاعدة البيانات: | BASE |
| تدمد: | 14796694 17448301 |
|---|---|
| DOI: | 10.2217/fon-2020-1225 |